Peter Goldschmidt recognized as one of the Top 100 by PharmaVOICE
Aug 10, 2015
FOR IMMEDIATE RELEASE
PharmaVOICE Magazine Announces the 2015 PharmaVOICE 100 and Red Jacket Award Honorees
When Peter Goldschmidt took up the role of President of Sandoz Inc., Head of North America, in July 2013, the company was in fourth position by volume share with 5.9% of the U.S. generics market. Just 18 months later, Sandoz is the fastest-growing growing generics company among the top 4 in the United States, with double-digit growth over the past year propelling it to the #3 position.
And Mr. Goldschmidt has plans to take Sandoz all the way to first place.
“My professional goal is to lead the best team in the generics industry in the United States,” he says.
From his first day Mr. Goldschmidt challenged every U.S. associate to “be the best,” with the goal of making Sandoz the No. 1 generics company in the United States. According to colleagues, be-the-best is more than a management mantra, at its heart is a belief that Mr. Goldschmidt instills in every associate, that their work is transforming patient outcomes by; increasing innovation, focusing on quality; and demonstrating courage and integrity.
The transformation of Sandoz began with Mr. Goldschmidt handpicking his senior management team to ensure his passion for excellence was shared throughout the business.
“If you have great talent, these team members will do everything to accomplish the vision,” he says. “For me, it’s not about inspiring in terms of motivating and showing the carrot. It’s about creating an environment where people can make great things happen and be the best they can be; they will work hard and with enthusiasm.”
Through Mr. Goldschmidt’s leadership Sandoz continues to grow, with significant investment in areas such as dermatology and biosimilars. Despite his short tenure, Mr. Goldschmidt has led Sandoz US through an unprecedented series of product firsts. In the past 12 months, Sandoz US doubled its launches year on year with 42 new products, five of which were first to file. One of these first-to-files was filgrastim, the first biosimilar application lodged with the FDA and the first to be approved under the Biologics Price Competition and Innovation Act. Sandoz also received the first approval on the generic version of Copaxone, a once-daily, 20mg, product for multiple sclerosis, by the FDA in April 2015 and launched in June. Finally, Sandoz forged a series of unique strategic product collaborations. And, Mr. Goldschmidt was personally involved in every deal for the U.S. business.
Mr. Goldschmidt demands a great deal from himself, his colleagues, and his family. He often brings stories of his family into town halls, telling how he expects them to be the best, with anecdotes about his children’s feats in swimming, soccer, and even the prom dance floor.
Mr. Goldschmidt has been recognized for his dedication to excellence, receiving the Chairman’s Leadership Development award (Novartis) in 2011.
TITUSVILLE, NJ - August 3, 2015 – Established more than 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life-sciences industry.
It is no surprise that you, our readers, have identified this year's honorees as outstanding leaders in the life-sciences industry today. These individuals demonstrate what it means to think differently, address the big challenges facing the industry, and lead teams through passionate inspiration.
The distinguished honorees are nominated by thousands of PharmaVOICE readers throughout the year and are selected based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and even competitors; have affected positive changes in their own organizations; as well as give back to their communities and other philanthropic causes.
The PharmaVOICE 100 honorees represent a broad cross-section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, generics, contract research, clinical operations, research and development, patient advocacy, patient recruitment, advertising, marketing, communications, technology, regulatory, and many others.
"This issue has become one of the most-anticipated and highly regarded publications of the year, and it is our privilege and honor to share the inspirational and motivational personal accounts of the men and women who are demonstrating exemplary leadership, changing the status quo, fostering innovation along the entire healthcare continuum, and building relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients," said Taren Grom, Editor and Cofounder of PharmaVOICE. "Last year, in celebration of 10 years of the PharmaVOICE 100, we launched the Red Jacket Award. This hall of fame award honors individuals who have been recognized multiple times throughout the years as a PharmaVOICE 100. Throughout their careers the five individuals being honored this year have demonstrated a commitment to transformative change, leadership, innovation, mentoring, and philanthropy. Their vision, impact, and influence are an inspiration to those throughout the life-sciences industry."
The 2015 Red Jacket Award honorees are: Jeffrey Aronin, Marathon Pharmaceuticals; Dr. Deborah Dunsire, Forum Pharmaceuticals; Alex Gorsky, Johnson & Johnson; Dr. Freda Lewis-Hall, Pfizer; and Leerom Segal, Klick Inc.
View the 2015 list of the PharmaVOICE 100: http://www.pharmavoice.com/article/2015-pharmavoice100-list-company/ This year, we are also pleased to announce the inaugural PharmaVOICE 100 Celebration, September 17, in New York City. This unique event is designed to convene our distinguished PharmaVOICE 100 and Red Jacket honorees as well as other leaders throughout the healthcare ecosystem to celebrate inspirational leadership, innovative thinking, and building business relationships. Please click here to learn more: http://www.pharmavoice.com/pv100-celebration/
PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE, with the largest distribution in its market sector, is delivered to more than 41,000 BPA-qualified subscribers, which include executives from pharmaceutical manufacturing, biotechnology, drug discovery, research & development, contract research, drug delivery, and device/diagnostic companies. The publication also targets decision makers at healthcare advertising, marketing, medical education, public relations, information technology, contract sales, traditional and nontraditional media, and other service support companies and organizations. The publication also reaches more than 100,000 users with its digital edition, which contains original exclusive bonus content.
PharmaVOICE's unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships.
PharmaVOICE's multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to a wide range of life-science sectors.